New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission

Single-dose baloxavir reduces household influenza transmission

A landmark study reveals that a single oral dose of baloxavir marboxil (baloxavir) significantly reduces the transmission of influenza within households, marking a major advancement in influenza management. The trial provides robust evidence that an antiviral treatment can curb the spread of influenza to close contacts.

New England Journal of Medicine Publishes Phase III Data Showing Single-dose Xofluza Significantly Reduces Influenza Virus Transmission

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Apr 25, 2025-

Antiviral Reduced Transmission of Influenza to Close Contacts

(MedPage Today) -- A single dose of the antiviral baloxavir marboxil (Xofluza) led to a lower incidence of influenza virus transmission to household contacts compared with placebo, a phase IIIb randomized trial showed. Five days after receiving...

NEJM Publishes Phase III Trial Data

can a Single Pill Stop the Flu in Its Tracks? The Promise of Xofluza and future… The post NEJM Publishes Phase III Trial Data appeared first on TIme News.

New Clinical Trial Data: Xofluza Makes History as First Antiviral to Reduce Flu Transmission by 32%

Groundbreaking NEJM study reveals Xofluza's potential to transform flu prevention. FDA and EMA submissions underway for new indication. See full trial data.

Study: Baloxavir cuts household flu transmission by 29%

In a flu pandemic setting, the drug could be used to curb household transmission, especially early in the response, the authors say.